These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 21186969)

  • 21. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
    Jain R; Babcock T; Burtea T; Dirks B; Adeyi B; Scheckner B; Lasser R; Renna J; Duncan D
    Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Childress AC; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Findling RL
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):210-7. PubMed ID: 24815910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Lloyd E; Johnson SA; Gunawardhana L; Arnold V
    J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):98-106. PubMed ID: 35230142
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
    Brown TE; Brams M; Gasior M; Adeyi B; Babcock T; Dirks B; Scheckner B; Wigal T
    Curr Med Res Opin; 2011; 27 Suppl 2():23-33. PubMed ID: 21973229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
    Coghill DR; Banaschewski T; Lecendreux M; Zuddas A; Dittmann RW; Otero IH; Civil R; Bloomfield R; Squires LA
    Eur Child Adolesc Psychiatry; 2014 Feb; 23(2):61-8. PubMed ID: 23708466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
    Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
    [No Abstract]   [Full Text] [Related]  

  • 27. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
    Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review of the safety of lisdexamfetamine dimesylate.
    Coghill DR; Caballero B; Sorooshian S; Civil R
    CNS Drugs; 2014 Jun; 28(6):497-511. PubMed ID: 24788672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
    Ginsberg L; Katic A; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Adler LA
    Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
    BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
    Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):52-62. PubMed ID: 31814294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.
    Waxmonsky JG; Waschbusch DA; Babinski DE; Humphrey HH; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    CNS Drugs; 2014 Jul; 28(7):665-77. PubMed ID: 24796970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
    Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
    CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Banaschewski T; Johnson M; Lecendreux M; Zuddas A; Adeyi B; Hodgkins P; Squires LA; Coghill DR
    CNS Drugs; 2014 Dec; 28(12):1191-203. PubMed ID: 25139785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Findling RL; Wu J; Kollins SH; Wang Y; Martin P; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):128-136. PubMed ID: 32233956
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Krishnan S; McGough JJ
    CNS Spectr; 2008 Jul; 13(7):614-20. PubMed ID: 18622366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
    Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
    J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
    Martin PT; Corcoran M; Zhang P; Katic A
    Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.